Ketamine safety: a detailed overview.

Ketamine was FDA-approved in 1970 and is on the World Health Organization's List of Essential Medicines. It has been used for decades in anesthesia and emergency medicine. Its use in psychiatric care is off-label — meaning it is prescribed for an indication other than the one for which it was originally approved. Off-label prescribing is a common and legal practice in medicine.

The safety profile of ketamine at the low doses used in supervised psychiatric care is well-characterized, though not zero-risk. A well-run program manages that risk through screening, low dosing, provider supervision, and clear patient education.

At low doses used in oral protocols, common effects include:

• Mild changes in perception (things may feel softer, slower, or more distant)
• Nausea, particularly during the first sessions
• Dizziness or light-headedness
• Sedation and drowsiness
• Temporary increases in blood pressure and heart rate
• Headache
• Vivid dreams or altered sleep the following night

Most of these effects are short-lived and resolve within the day of a session. Report any effect that concerns you to your provider.

Dissociation

Ketamine can produce a subjective experience of emotional or perceptual distance from the body or surroundings. At low oral doses this is usually mild and time-limited. Occasionally, patients find it uncomfortable; the intake evaluation, dose selection, and setting are designed to minimize distress.

Cardiovascular effects

Ketamine transiently raises blood pressure and heart rate. This is one reason screening for uncontrolled hypertension and cardiovascular disease is standard before treatment.

Urinary tract issues at high, long-term doses

Cases of urinary tract irritation and cystitis have been reported primarily with heavy, long-term recreational use — not with low-dose supervised programs. Even so, dosing and duration are carefully managed to keep exposure conservative.

Abuse potential

Ketamine is a scheduled medication with recognized abuse potential. Supervised, low-dose protocols with screening for substance use history and controlled dispensing are designed to minimize this risk.

Ketamine may not be appropriate for people with:

• Uncontrolled cardiovascular disease or uncontrolled hypertension
• History of severe cardiac arrhythmias without cardiology clearance
• Active psychosis or a history of psychotic disorders
• Active mania or uncontrolled bipolar disorder
• Active pregnancy or breastfeeding
• Certain active substance use disorders
• Known allergy or hypersensitivity to ketamine
• Certain interacting medications

This list is not exhaustive. Candidacy is a clinical determination made after a comprehensive intake evaluation.

Several classes of medications and substances may interact with ketamine, including benzodiazepines, opioids, MAOIs, some blood pressure medications, other CNS depressants, alcohol, and recreational substances. Bring a complete and up-to-date medication list to your evaluation.

Never start, stop, or change the dose of a prescribed medication on your own. Any adjustments should always happen under the supervision of the prescribing provider.

Do not drive, operate machinery, sign legal documents, or make major decisions on the day of a session. Plan for rest, quiet, and hydration. Because our program is at-home, you do not need to travel.

Your provider will explain the check-in cadence for your plan, what to monitor between sessions, and how to reach the care team through secure messaging. Report new or worsening symptoms between sessions — do not wait for the next appointment.

Low-dose oral ketamine used within a supervised, well-screened program has a generally acceptable safety profile for appropriate patients. Safety comes from the whole system — screening, dosing, supervision, and integration — not from the medication alone.

For a shorter summary, see our Safety information page.